Respiratory syncytial virus infections Trials in Baltimore, United States
Conditions / Respiratory syncytial virus infections / Baltimore, United States
Respiratory syncytial virus infections has been the subject of sustained clinical investigation across multiple research sites.
22 total trials for this combination
Showing top 10 of 22 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03102034 | Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age | COMPLETED | PHASE1 |
| NCT02794870 | Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age | COMPLETED | PHASE1 |
| NCT00493285 | Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age | COMPLETED | PHASE1 |
| NCT02325791 | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants | COMPLETED | PHASE3 |
| NCT02890381 | Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age | TERMINATED | PHASE1 |
| NCT03227029 | Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age | COMPLETED | PHASE1 |
| NCT00384462 | Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants | COMPLETED | — |
| NCT00031473 | Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients | TERMINATED | PHASE3 |
| NCT03636906 | Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV | COMPLETED | PHASE1/PHASE2 |
| NCT00129766 | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children | COMPLETED | PHASE3 |